Navigation Links
MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
Date:7/9/2012

KENNESAW, Ga., July 9, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTC-BB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the second quarter ended June 30, 2012, will be released before the opening of the market on Thursday, July 26, 2012. MiMedx will host a live broadcast of its second quarter conference call on Thursday, July 26, 2012 at 10:30am Eastern Time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.

About the Company MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthope
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Record First Quarter Results
2. MiMedx Exceeds Revenue Goal for First Quarter of 2012
3. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
4. MiMedx Group Announces 2011 Results
5. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
6. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
7. MiMedx Group Completes $5,000,000 Private Placement
8. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
9. Mindray Renews Agreement with HealthTrust Purchasing Group, L.P. to Provide Patient Monitoring Equipment
10. Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research
11. Cord Blood America Announces Agreement To Restructure Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... WriteResult, LLC – a premier provider ... with a team of researchers from Yale University’s School ... Collaborative to provide electronic questionnaire data collection through use ... started in May, aims to evaluate the impact of ... to and participation in urban agriculture to impact their ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... ... of surrogacy. West Coast Surrogacy, Inc. founder/director Amy Kaplan, an expert in reproductive ... carrier. , ... December 29, 2009 -- Children – they’re everywhere, especially during the holidays. A chubby ...
... , , , , , , , ... provider of biopharmaceutical products in China, announced today,that it has filed ... a human clinical trial for its vaccine,against human enterovirus 71 (EV ... first clinical trial application for HFMD vaccine,submitted in China. , ...
... , TSX symbol: SBS , CALGARY, ... an update today on its progress on plant-produced Apo ... between Pfizer Inc. and The Medicines Company, of Parsippany, ... exclusive rights to Pfizer,s Apo AI(Milano) program is a ...
Cached Biology Technology:Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 2Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 3Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 4Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 5Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4SemBioSys updates progress on Apo AI(Milano) 2SemBioSys updates progress on Apo AI(Milano) 3
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... cells grow fast. That,s an essential characteristic of what makes ... and are continuously growing and dividing, far outstripping our normal ... metabolism. CSHL Professor Adrian Krainer and his team ... process and in the process specifically kill cancer cells. ...
... at the University of Liverpool have found that, like ... that describes multiple health issues that occur in the ... condition occurs when a number of health problems, such ... together, with the potential to increase the risk of ...
... The UK Government has recently imposed a ban on importing ... fungal disease Chalara, which kills the trees and has entered ... researchers argue that the nursery trade, horticultural stakeholders and the ... risks to tree health posed by imported plant pathogens. They ...
Cached Biology News:Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 2Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 3Obese dogs at risk of health condition experienced by humans 2Action needed to prevent more devastating tree diseases entering the UK 2
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: